CAPTRUST Financial Advisors
ACRS icon

CAPTRUST Financial Advisors’s Aclaris Therapeutics ACRS Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-61
Closed -$1K – 2083
2022
Q2 		$1K Buy
+61
New +$855 ﹤0.01% 4613

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

CAPTRUST Financial Advisors's ACRS Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2022, closing a stake of 61 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in ACRS in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 127 funds tracked by Wall St. Rank hold ACRS as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Aclaris Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 61 Aclaris Therapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Aclaris Therapeutics in Q2 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Aclaris Therapeutics position peaked at $1K in Q2 2022.
  • 127 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.